ArticleBioMed research international2026
Network Pharmacology-Based Identification of Potential Targets and Mechanisms of Isoginkgetin in Gastric Cancer.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIsoginkgetin (ISO) is a natural flavonoid with potential anticancer effects. However, the anticancer mechanisms of ISO in gastric cancer remain insufficiently explored.
methodsNetwork pharmacology, TCGA data analysis, and molecular docking were employed to identify potential ISO targets and their involvement in gastric cancer. Differentially expressed genes (DEGs) in gastric cancer were compared with ISO targets to find overlapping genes. Functional enrichment analysis was conducted to determine key biological pathways. Cytoscape-MCODE was used to identify hub genes, and molecular docking assessed the binding stability between ISO and these hub genes.
resultsA total of 107 potential ISO targets were identified, of which 66 overlapped with gastric cancer DEGs. Functional enrichment analysis indicated involvement in cell cycle regulation, cellular senescence, and the PI3K-Akt signaling pathway. Ten hub genes (GSK3B, TERT, CCNT1, CCNB3, CCNB2, CREB1, CCNA2, CCNB1, CDK1, and ESR1) were identified using Cytoscape-MCODE. Most genes were highly expressed in tumor tissues and positively correlated, with some significantly associated with patient survival. Molecular docking demonstrated stable binding between ISO and the hub genes.
conclusionIn conclusion, this study systematically explored the molecular targets and potential mechanisms of ISO in gastric cancer, providing a preliminary theoretical basis for further research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.